Olpasiran leads to significant and sustained reduction in OxPL on apolipoprotein B<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Feb. 21, 2025 (HealthDay News) — Olpasiran, a small interfering RNA, which blocks lipoprotein(a) (Lp[a]) production, leads to a significant and sustained reduction in oxidized phospholipids (OxPL) on apolipoprotein B (apoB), according to a study published online Feb. 12 in JAMA Cardiology<\/em>.<\/p>\n Robert S. Rosenson, M.D., from Mount Sinai Hospital in New York City, and colleagues examined the effect of olpasiran on OxPL, high-sensitivity interleukin 6 (hs-IL-6), and high-sensitivity C-reactive protein (hsCRP) in a multicenter, phase 2, dose-finding randomized trial involving 281 patients with atherosclerotic cardiovascular disease and Lp(a) levels >150 nmol\/L. Participants were randomly assigned to receive one of four active subcutaneous doses of olpasiran versus placebo: 10 mg every 12 weeks (Q12W); 75 mg Q12W; 225 mg Q12W; or 225 mg every 24 weeks (Q24W).<\/p>\n The researchers found that the placebo-adjusted mean percentage change in OxPL on apoB (OxPL-apoB) concentration from baseline to week 36 was \u221251.6, \u221289.7, \u221292.3, and \u221293.7 percent for the 10-mg Q12W, 75-mg Q12W, 225-mg Q12W, and 225-mg Q24W doses, respectively, with maintenance of these effects observed to 48 weeks (\u221250.8, \u2212100.2, \u2212104.7, and \u221285.8 percent, respectively). For patients treated with olpasiran, there was a strong correlation between percentage reduction in Lp(a) and OxPL-apoB (r<\/em> = 0.79). No significant impact was seen on hs-CRP or hs-IL-6 for olpasiran versus placebo to weeks 36 or 48.<\/p>\n “Olpasiran leads to a significant reduction in OxPL on apoB,” the authors write. “It remains unknown whether these observed effects may offer incremental benefit beyond olpasiran’s effect of Lp(a) lowering alone.”<\/p>\n Several authors disclosed ties to pharmaceutical companies, including Amgen, which manufactures olpasiran and funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n